Quoin pharmaceuticals provides corporate update and announces fourth quarter and 2023 financial results

Company reported positive initial clinical data for qrx003 from first six evaluable subjects in ongoing open-label netherton syndrome study with positive benefits observed across a number of clinical endpoints
QNRX Ratings Summary
QNRX Quant Ranking